Case Studies

Efgartigimod

Efgartigimod (ARGX-113) was designed as a human IgG1 antibody Fc-fragment, a natural ligand of the neonatal Fc receptor (FcRn). FcRn is known to extend half-life and availability of pathogenic IgG antibodies.

Efgartigimod has been engineered for increased affinity to FcRn and was built in collaboration with Prof. E. Sally Ward, Ph.D. who is a pioneer of FcRn biology.

IIP Collaboration

Discover how our collaborative model transforms ideas into impact through scientific partnerships.

ARGX-118

ARGX-118 was designed as a highly differentiated antibody against Galectin-10, the protein of Charcot-Leyden crystals, which are implicated as a major contributor to severe asthma and to the persistence of mucus plugs.

ARGX-118 was built in collaboration with Prof. Bart Lambrecht, M.D., Ph.D. who identified the first novel airway inflammation target in decades.

ARGX-115

ARGX-115 (now ABBV-151) was designed as a humanized monoclonal antibody inhibitor of GARP- TGF-β1 and is in development by AbbVie for the treatment of cancer.

ARGX-115 was built in collaboration with Prof. Sophie Lucas, M.D., Ph.D. who has been a leader in checkpoint biology research since 1985.

Adimanebart

Learn how adimanebart (previously ARGX-119), a humanized monoclonal antibody (mAb) specifically designed to activate muscle-specific kinase (MuSK), emerged from our Immunology Innovation Program to redefine what’s possible in antibody-based therapies.

Developed in collaboration with Maartje Huijbers, Ph.D., Associate Professor and Research Group Leader at Leiden University Medical Center, and Steve Burden, Ph.D., during his tenure at NYU.